Myth 3 : The process of guideline development
has been influenced by the pharmaceutical industry.
Truth: When the National Heart, Lung, and Blood
Institute has begun the process of developing recommendations , they
have established a disclosure policy to prevent the pharmaceutical
industry to influence these guidelines for
prevention and treatment.
The writing group chairs , other stakeholders and the
expert evaluators , completely and accurately followed the policy - in some
cases, beyond that required by policy to further
establish the integrity of the panel.
In addition, committee members were asked to declare any
conflict of interest information for complete training in advance of the
proceedings.
Members of conflict were invited to recuse himself from
voting on all aspects of the Directive where a conflict may exist.
These policies were in
force when this effort began in 2008 until the process was transferred to the ACC / AHA 2013.
In the interest of
transparency, the ACC / AHA requested that the authors of panels restart
information as of July 2013.
No expert reviewers ACC / AHA were
relevant relationships with industry.
Importantly, almost all statins, including very powerful,
are now available in generic form , and guidelines call for the use of
cholesterol-lowering drugs that have proven they can prevent heart
attacks.
The Source
The Source
